Investor Relations

Overview

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of novel antibiotics to treat serious infections. Nabriva Therapeutics has two products: Xenleta™ (lefamulin), recently approved by the FDA for both Oral and IV use, and CONTEPO (fosfomycin) for injection, we submitted an NDA for CONTEPO, a potential first-in-class epoxide antibiotic in the United States for complicated urinary tract infections (cUTIs), including acute pyelonephritis (AP). Our corporate headquarters are in Dublin, Ireland with offices and labs located in Vienna, Austria and King of Prussia, PA.

Events & Presentations

Upcoming
More events are coming soon.
Prior

Wednesday December 4, 2019 4:30 PM EST
Piper Jaffray Healthcare Conference

Tuesday November 12, 2019 4:30 PM EST
Nabriva Third Quarter 2019 Financial Results Call

Wednesday October 2, 2019 1:50 PM EDT
2019 Cantor Global Healthcare Conference

SEC Filings

Filing date Description Form Filing Group View

Report of unscheduled material events or corporate event

8-K
Current Reports
View HTML

Quarterly report which provides a continuing view of a company's financial position

10-Q
Quarterly Filings
View HTML EX-101.INS - EX-101.INS

Report of unscheduled material events or corporate event

8-K
Current Reports
View HTML

Investor Contacts

E-mail: IR@nabriva.com